Targeting ENT1 and adenosine tone for the treatment of ...

Targeting ENT1 and adenosine tone for the treatment of ... - PubMed

Huntington's disease (HD) is caused by an abnormal CAG expansion in the exon 1 of huntingtin gene. The treatment of HD is an unmet medical ...

The inhibition of ENT1 can enhance extracellular adenosine level and be a potential therapeutic approach for treating HD.

Targeting ENT1 and adenosine tone for the treatment of ...

Targeting adenosine tone for treating HD was examined in R6/2 mice by genetic removal of ENT1 and by giving an ENT1 inhibitor, respectively. The results showed ...

Targeting ENT1 and adenosine tone for the treatment of ...

Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. Human molecular genetics (2017-01-11). Yu-Han Kao, Meng-Syuan Lin, Chiung-Mei Chen ...

(PDF) Targeting ENT1 and adenosine tone for the treatment of ...

Targeting adenosine tone for treating HD was examined in R6/2 mice by genetic removal of ENT1 and by giving an ENT1 inhibitor, respectively. The results showed ...

Targeting the equilibrative nucleoside transporter ENT1 in ...

All these experimental results brought us to consider the possibility of a low adenosine tone in this HD animal model. By means of in vivo microdialysis ...

ddw402.pdf - Oxford Academic

Targeting adenosine tone for treating HD was examined in R6/2 mice by genetic removal of ENT1 and by giving an ENT1 inhibitor, respectively. The ...

Equilibrative nucleoside transporter ENT1 as a biomarker of ...

ENT1 was also demonstrated in postmortem brain tissue from HD patients. •. Adenosine and ENT1 can constitute biomarkers an therapeutic targets for HD. Abstract.

The Role of Adenosine Tone and Adenosine Receptors in ...

Targeting ENT1 in phenotypic HD models. Because ENT1 is upregulated while adenosine tone is reduced in both animal models and HD patients, it is ...

Equilibrative Nucleoside Transporters-1 Inhibitors Act as Anti ...

Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. Hum. Mol. Genet. 26, 467–478. doi: 10.1093/hmg/ddw402. PubMed ...

[PDF] Equilibrative nucleoside transporter ENT1 as a biomarker of ...

Targeting ENT1 and adenosine tone for the treatment of Huntington's disease ... therapeutic approach for treating HD. Expand. 34 Citations · PDF. Add to ...

Equilibrative nucleoside transporter 1 inhibition rescues energy ...

... adenosine tone would impact Tau pathology, associated molecular alterations and subsequent neurodegeneration. We demonstrated that treatment ...

Deletion of equilibrative nucleoside transporter 2 disturbs energy ...

Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. Hum. Mol. Genet., 26 (2017), pp. 467-478, 10.1093/hmg/ddw402 · View in Scopus ...

Emerging Roles of Nucleoside Transporters - Frontiers

Thus, ENT1 inhibition could be a potential therapeutic target for treating ... Targeting ENT1 and adenosine tone for the treatment of Huntington's ...

Targeting myocardial equilibrative nucleoside transporter ENT1 ...

When given i.v., the Adora1 adenosine receptor has been implicated in mediating the heart rate–slowing effects of adenosine treatment of ...

A2AR Agonist-1 (JMF 1907, CAS Number: 41552-95-8)

Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. Hum. Mol. Genet. 26(3), 467-478 (2017). Technical Support & Resources.

A New Drug Design Targeting the Adenosinergic System for ... - PLOS

... adenosine transporter (ENT1). T1-11 was originally isolated from a ... adenosine tone and is a potential candidate for treating HD. In addition to ...

ENT1 Inhibitors - Alzheimer's Drug Discovery Foundation

Adenosine tone in the brain is controlled by multiple proteins. Equilibrative nucleoside transporter 1. (ENTs) and concentrative nucleoside transporters (CNTs) ...

Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity ...

Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. Nat ... Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.

Targeting the adenosinergic system: Ligand binding kinetics and ...

Next to only ENT1 inhibitor administration, a combination of ENT1 and adenosine ... Targeting ENT1 and adenosine tone for the treatment of. Huntington's disease ...